[{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"PTI-125","moa":"Filamin A","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"PTI-125","moa":"Filamin A","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"PTI-125","moa":"Filamin A","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"PTI-125","moa":"Filamin A","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"PTI-125","moa":"Filamin A","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sumifilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sumifilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sumifilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.20000000000000001,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Evonik","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Cassava Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sciences \/ Cassava Sciences"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Simufilam","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Simufilam","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"B. Dyson Capital Advisors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Simufilam","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.13,"dosageForm":"Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ B. Dyson Capital Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ B. Dyson Capital Advisors"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cassava Sciences \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Cassava Sciences
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
